Products from BPS Bioscience require a minimum order value above 400€Applications: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
Assay Conditions: 25 mM Tris HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl
2, and 0.1 mg/ml BSA, 20 µM BPS HDAC class 2a substrate (Catalog #50040), and HDAC7 (0.16 - 10 ng). Incubation condition: 30 min at 37°C, followed byHDAC developer (Catalog #50030) for 15 min at room temperature. Fluorescence intensity is measured at ex360/em460.
Description: Human HDAC7 , GenBank Accession No. AY302468, a.a. 518-end, with N-terminal GST-tag, MW= 78 kDa, expressed in baculovirus expression system.
Format: Aqueous buffer solution
Formulation: 45 mM Tris-HCl, pH 8.0, 124 mM NaCl, 2.4 mM KCl, 20 mMglutathione, and 10% glycerol.
Genbank: AY302468
Storage Stability: At least 6 months at -80°C.
Tags: N-terminal GST-tag
Uniprot: Q8WUI4
Unit Definition: One U =1 pmol of acetyl group removed/min/µg of enzyme
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Chakraborty S. (2006) J.Biol.Chem. 281(46):35070-80.
2. Wolfgang, F. (2001) J. Biol. Chem. 276(38): 35826-35835.Application References:
1. Abdel-Atty, M.M., et al. Bioorg Chem. 2014 Dec;57:65-82. doi: 10.1016/j.bioorg.2014.08.006. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
2. Wang, C., et al. J Med Chem. 2014 Oct 9;57(19):7999-8009. doi: 10.1021/jm500872p. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
3. Schroeder, F.A., et al. PLoS One . 2013 Aug 14;8(8):e71323. doi: 10.1371/journal.pone.0071323. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013)
4. Fass, D.M., et al. Neuropharmacology. 2013 Jan; 64: 81–96. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
5.
FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)